Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-04-23 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司股东大会议事规则（2024.04）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Shareholders' Meeting Rules" or "Rules of Procedure for the Shareholders' General Meeting". It is a detailed procedural document outlining the governance, convening, proposal submission, voting, and other operational rules for shareholders' meetings of Beijing Shuanglu Pharmaceutical Co., Ltd. It does not contain financial statements, audit opinions, voting results, or announcements of meetings, but rather the internal rules governing the conduct of shareholder meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is sufficient and it is not an announcement or a brief notice, but a full set of governance rules. Therefore, the appropriate classification is CGR with high confidence.
2024-04-23 Chinese
北京双鹭药业股份有限公司独立董事专门会议工作制度（2024.04）
Governance Information Classification · 95% confidence The document is titled as a working system for the Independent Directors' Special Meeting of Beijing Shuanglu Pharmaceutical Co., Ltd., dated April 2024. It outlines governance procedures, responsibilities, meeting protocols, and decision-making rules specifically for independent directors. There is no financial data, no mention of financial results, no shareholder voting results, no capital changes, no legal proceedings, no earnings or annual report content. The document is a governance-related internal regulation or policy document. It fits best under Governance Information (CGR) as it details the company's internal rules and governance practices related to independent directors' meetings.
2024-04-23 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2023 Annual Report Summary" of Beijing SL Pharmaceutical Co., Ltd. It contains detailed information about the company's business, products, and financial matters for the year 2023. The length is substantial (15,000 characters), indicating it is not a brief announcement but a substantive report. The content includes business overview, product descriptions, and financial distribution plans, which are typical components of an Annual Report. There is no indication that this is merely an announcement of a report or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-23 Chinese
北京双鹭药业股份有限公司关于董事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new board of directors for the company Beijing Shuanglu Pharmaceutical Co., Ltd. It details the nomination of candidates for the ninth board, including both independent and non-independent directors, their qualifications, and compliance with relevant laws and regulations. The document also mentions the upcoming shareholder meeting to approve these nominations. There is no financial data, audit information, or report attached; it is purely an announcement about board changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is 3855 characters, which is consistent with an announcement rather than a full report.
2024-04-23 Chinese
独董候选人声明与承诺-程隆云
Board/Management Information Classification · 100% confidence The document is a detailed declaration and commitment statement by an independent director candidate for Beijing Shuanglu Pharmaceutical Co., Ltd. It includes extensive statements about qualifications, compliance with laws and regulations, and commitments related to the role of an independent director. There is no financial data, no report of financial results, no voting results, no announcement of a meeting, no legal proceeding update, and no mention of share transactions or capital changes. The content is focused on board/management information specifically about the nomination and qualifications of a board member candidate. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification, so it is not RNS or RPA.
2024-04-23 Chinese
2023年年度审计报告
Regulatory Filings
2024-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.